Australia’s CSL delays spin-off as US flu vaccine rates decline

Australian biotech CSL delayed its planned spin-off of vaccine division CSL Seqirus and significantly cut its full-year earnings guidance, citing a larger-than-expected decline in U.S. flu vaccination rates amid broader vaccine headwinds in the country. The company now projects revenue growth of 2-3% and NPATA growth of 4-7%, down from previous forecasts, leading to a 16.6% share price drop to a seven-year low. The demerger is now contingent on market conditions maximizing shareholder value, though its CSL Behring blood plasma division is expected to maintain robust growth.

Analysis

Australian biotech CSL has delayed the spin-off of its CSL Seqirus vaccine division and significantly cut its full-year earnings guidance for the financial year ending June 2026. This revision, driven by a larger-than-expected decline in U.S. flu vaccination rates, resulted in a 16.6% share price drop, reaching a seven-year low. The company now projects revenue growth of 2-3% (down from 4-5%) and NPATA growth of 4-7% (down from 7-10% on a constant currency basis).

The downgrade is attributed to persistent U.S. vaccine headwinds, including reduced research funding and leadership changes at the CDC under Health Secretary Robert F. Kennedy Jr., alongside the FDA's independent recommendation of virus strains. Rival Sanofi also reported pressure on U.S. flu and COVID-19 vaccine sales, citing a "negative buzz," indicating a systemic challenge for vaccine manufacturers in the U.S.

The CSL Seqirus demerger, initially planned by next June, is now contingent on market conditions that maximize shareholder value, signaling a strategic pause. Despite vaccine division challenges, CSL's CSL Behring blood plasma division is expected to maintain robust growth, supported by a strong balance sheet and cash generation. This bifurcation in portfolio performance suggests the plasma business may partially offset vaccine segment weakness.

Key Decisions for Investors

• Investors should re-evaluate their CSL holdings given the significant guidance downgrade and the delay of the CSL Seqirus spin-off, which impacts the initial restructuring thesis.
• Closely monitor developments in the U.S. vaccine market, including regulatory changes and public sentiment, as these broader headwinds could continue to affect CSL's Seqirus division and other vaccine producers like Sanofi.
• Assess the projected robust growth of the CSL Behring blood plasma division and its ability to offset the underperformance of the vaccine segment, considering its contribution to overall company profitability and cash flow.
• Anticipate and review revised analyst price targets and earnings forecasts for CSL, as these will reflect the market's updated expectations following the guidance cut.